Cynapsus Therapeutics, which is developing a sublingual film for the OFF episodes of Parkinson's disease, filed on Friday with the SEC to raise up to $60 million in an initial public offering. Cynapsus currently trades on the Toronto Stock Exchange under...read more
In its second attempt to go public, biopharmaceutical firm Acorda Therapeutics priced 5.5 million shares at $6, well below its initially proposed $11-$13 range. The Hawthorne, NY based company, which markets and develops therapies to improve neurological...read more
Acorda Therapeutics, a developer of drugs for the treatment of spinal cord injuries and MS, sliced its range -46% to $6 to $7 from $11 to $13. The offering size remains the same at 5.5 million shares. Banc of America is the lead underwriter on the deal. The...read more
Acorda Therapeutics, a developer of drugs for the treatment of spinal cord injuries and MS, filed terms Monday morning. The NY based company plans to offer 5.5 million shares at a range of $11 to $13. Banc of America is the lead manager on the deal....read more
Parkinson's biotech Cynapsus Therapeutics files for a $60 million US IPO
Cynapsus Therapeutics, which is developing a sublingual film for the OFF episodes of Parkinson's disease, filed on Friday with the SEC to raise up to $60 million in an initial public offering. Cynapsus currently trades on the Toronto Stock Exchange under...read more
Biopharmaceutical firm Acorda Therapeutics prices 5.5mm shares at $6
In its second attempt to go public, biopharmaceutical firm Acorda Therapeutics priced 5.5 million shares at $6, well below its initially proposed $11-$13 range. The Hawthorne, NY based company, which markets and develops therapies to improve neurological...read more
Drug developer Acorda Therapeutics cuts range -46%
Acorda Therapeutics, a developer of drugs for the treatment of spinal cord injuries and MS, sliced its range -46% to $6 to $7 from $11 to $13. The offering size remains the same at 5.5 million shares. Banc of America is the lead underwriter on the deal. The...read more
Drug developer Acorda Therapeutics sets range, offering size
Acorda Therapeutics, a developer of drugs for the treatment of spinal cord injuries and MS, filed terms Monday morning. The NY based company plans to offer 5.5 million shares at a range of $11 to $13. Banc of America is the lead manager on the deal....read more